Resolution of headache and papilledema in idiopathic intracranial hypertension associated with inhibition of Na+-K+-2Cl- cotransport.

Abstract

Medical treatment of idiopathic intracranial hypertension is often ineffective. Cerebrospinal fluid diversion or optic nerve sheath fenestration is employed when medical therapy fails. Here, we describe a case of a 13-year-old girl with idiopathic intracranial hypertension refractory to long-term trials of acetazolamide and furosemide at maximally tolerated doses. After declining surgical intervention despite progression of her visual symptoms, a trial of bumetanide (0.25 mg daily) monotherapy was successful in resolution of the patient's symptoms. These results suggest bumetanide could be effective in the treatment of idiopathic intracranial hypertension, perhaps by restoring the balance between cerebrospinal fluid formation and absorption and/or by altering the volume or ionic composition of the brain's extracellular fluid compartment.

• Authors: Kristopher T Kahle, Brian P Walcott, Kevin J Staley
• Journal: Journal of child neurology (J Child Neurol) Vol. 26 Issue 2 Pg. 205-8 (Feb 2011) ISSN: 1708-8283 [Electronic] United States
• PMID: 21285039 (Publication Type: Case Reports, Journal Article)

Chemical References

• Sodium Potassium Chloride Symporter Inhibitors
• Bumetanide

Topics

• Adolescent
• Bumetanide (therapeutic use)
• Disease Progression
• Female
• Headache (drug therapy, etiology)
• Humans
• Papilledema (drug therapy, etiology)
• Pseudotumor Cerebri (complications, drug therapy)
• Sodium Potassium Chloride Symporter Inhibitors (therapeutic use)
• Treatment Outcome